AbbVie buys $2.1bn Capstan, adding new in vivo CAR-T to pipeline
Pharmaceutical Technology
JULY 1, 2025
According to William Blair, forecast revenue rate from 2024 to 2029 growth rate for AbbVie trails only Eli Lilly and Sanofi, representing an “attractive opportunity” for long-term investors. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Sign up for our daily news round-up!
Let's personalize your content